




Instance: composition-en-a8827a69a4f2a8d5bccee719c4738936
InstanceOf: CompositionUvEpi
Title: "Composition for cufence Package Leaflet"
Description:  "Composition for cufence Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpc0028cb0d3397ea4065a3d3cc7305a60)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - cufence"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Cufence is and what it is used for </li>
<li>What you need to know before you take Cufence </li>
<li>How to take Cufence </li>
<li>Possible side effects </li>
<li>How to store Cufence </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What cufence is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What cufence is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Cufence is a medicine used for the treatment of Wilson s disease in adults, adolescents and children 
aged 5 years or older. It is for use by patients who cannot take another medicine, D-Penicillamine, 
because of side effects. </p>
<p>Cufence contains the active substance trientine, a copper-chelating agent that is used to remove excess 
of copper from the body. Cufence attaches to the copper, which is then passed from the body.  </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take cufence"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take cufence"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Cufence </p>
<p>If you are allergic to trientine or any of the other ingredients of this medicine (listed in section 6).  </p>
<p>Signs of an allergic reaction include rash, itching, swelling of the face, fainting and breathing 
problems. </p>
<p>Warnings and precautions  </p>
<p>Your doctor will need to regularly check for symptoms of the disease and copper levels in your blood 
and urine. Regular monitoring is especially important at the start of your treatment or when your dose 
is changed, in growing children and pregnant women to ensure that copper levels are maintained at a 
suitable level. The doctor may need to increase or decrease your dose of Cufence.  </p>
<p>Nervous system problems can occur (for example, shaking, lack of coordination, slurred speech, 
muscle stiffness and worsening of muscle spasms), especially in patients just starting treatment with 
Cufence. If you notice these whilst taking Cufence, you must tell your doctor immediately. </p>
<p>Lupus-like reactions (symptoms may include persistent rash, fever, joint pain, and tiredness) have 
been reported in some patients switched to trientine medicine after penicillamine medicine. However, 
it was not possible to determine if the reaction was due to trientine or to previous penicillamine 
treatment. </p>
<p>Other medicines and Cufence </p>
<p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. </p>
<p>If you are taking iron tablets or medicines that neutralise the acid in your stomach, leave at least 
2 hours before or after you have taken Cufence because they may reduce Cufence s effect. 
It is recommended that trientine is taken at least one hour apart from any other medicinal product. </p>
<p>Cufence with food and drink </p>
<p>Take this medicine with water only. Do not take it with other drinks, milk or food because they may 
reduce the medicine s effect. Avoid eating or drinking (except water) for 2 hours before and 1 hour 
after taking Cufence. </p>
<p>Pregnancy and breast-feeding </p>
<p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor or pharmacist for advice before taking this medicine. It is very important to continue 
treatment to maintain normal copper levels during pregnancy. You and your doctor should fully 
discuss the potential benefits of treatment whilst considering any possible risks that there may be. 
Your doctor will advise you which treatment and which dose is best in your situation. If you become 
pregnant whilst taking Cufence, talk to your doctor. </p>
<p>If you are pregnant and taking Cufence, you will be monitored throughout your pregnancy for any 
effects on the baby or changes in your copper levels.  </p>
<p>The limited information available suggests that Cufence does not pass into breast milk, but it is not 
certain that there is no risk to the baby.  It is important to tell your doctor if you are breast-feeding or 
plan to do so. Your doctor will then help you decide whether to stop breast-feeding or to stop taking 
Cufence, considering the benefit of breast-feeding to the baby and the benefit of Cufence to the 
mother. Your doctor will decide which treatment and which dose is best in your situation. </p>
<p>Driving and using machines </p>
<p>Trientine is not likely to have an effect on your ability to drive or use machines. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take cufence"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take cufence"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure. </p>
<p>Adults (including the elderly) </p>
<p>The usual dose is between 800 and 1 600 mg per day, to be taken by mouth. </p>
<p>Use in children and adolescents (5 to 17 years) </p>
<p>In children and adolescents, the dose depends on age and body weight and will be adjusted by your 
doctor. At the start of treatment the dose varies between 400 and 1 000 mg per day. </p>
<p>Method of administration </p>
<p>Your doctor will decide the correct dose for you. 
The total daily dose can be divided into 2 to 4 smaller doses, as indicated by your doctor. Swallow the 
capsules whole with a drink of water on an empty stomach, at least 1 hour before or 2 hours after food.  </p>
<p>Patients who have difficulties swallowing should contact their doctor. </p>
<p>If you take more Cufence than you should </p>
<p>If you take more medicine than you should, you may get nausea, vomiting and dizziness. You must 
contact your doctor or another health care provider immediately. </p>
<p>If you forget to take Cufence </p>
<p>If you forget to take a dose take your next dose at its usual scheduled time. 
Do not take a double dose to make up for a forgotten dose. </p>
<p>If you stop taking Cufence </p>
<p>This medicine is for long-term use because Wilson s disease is a life-long condition. Do not stop or 
change your treatment without speaking with your doctor even if you feel better. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. 
Occasionally (frequency unknown; cannot be estimated from available data), treatment with this 
medicine can cause inflammation of the small intestine or colon.  If you have any of the following side 
effects contact your doctor immediately:</p>
<ul>
<li>Severe stomach pains </li>
<li>Persistent diarrhoea </li>
<li>Nervous system problems (for example shaking, lack of coordination, slurred speech, muscle 
stiffness, worsening of muscle spasms).  </li>
</ul>
<p>Other side effects may include: 
Common (may affect up to 1 in 10 people) 
- Nausea (especially when starting treatment) </p>
<p>Uncommon (may affect up to 1 in 100 people) 
- Skin rashes 
- Anaemia (you may feel unusually tired) </p>
<p>Reporting of side effects </p>
<p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects, you can help provide more information on the 
safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store cufence"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store cufence"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use after the expiry date which is stated on the bottle label and outer carton.  The expiry date 
refers to the last day of the month. <br />
Use within 3 months after first opening the bottle. Keep the bottle tightly closed in order to protect 
from moisture. Do not use if the capsules become sticky or wet.  </p>
<p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to 
dispose of medicines no longer required.  These measures will help to protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Cufence contains </p>
<p>The active substance is trientine.<br />
- Each capsule of Cufence 100mg contains 150 mg trientine dihydrochloride, equivalent to 100 mg 
trientine. 
- Each capsule of Cufence 200 mg contains 300 mg trientine dihydrochloride, equivalent to 200 mg 
trientine. </p>
<p>The other ingredients are<br />
- Capsule content: Magnesium stearate, Colloidal anhydrous silica 
- Capsule shell: Gelatin, Titanium dioxide (E171) 
- Printing ink: Shellac, Propylene glycol, Titanium dioxide (E171), Iron oxide black (E172), Iron 
oxide yellow (E172) </p>
<p>What Cufence looks like and contents of the pack  </p>
<p>Cufence 100 mg hard capsules 
White opaque HDPE bottle with an HDPE child-resistant screw cap and induction heat seal liner with 
a sachet of dried silica gel as desiccant. Each hard capsule is white oval-shaped size 3 (15.8 mm x 
5.85 mm) with  Cufence 100  printed in grey ink. </p>
<p>Pack size: one bottle of 200 hard capsules. </p>
<p>Cufence 200 mg hard capsules 
Amber glass bottle with a polypropylene cap and induction heat seal liner with a sachet of dried silica 
gel as desiccant. Each hard capsule is white oval-shaped size 0 (21.8 mm x 7.66 mm) with  Cufence<br />
printed in grey ink. </p>
<p>Pack size: one bottle of 100 hard capsules.  </p>
<p>Not all pack-sizes may be marketed. </p>
<p>Marketing Authorisation Holder 
Univar Solutions BV 
Schouwburgplein 3012 CL Rotterdam 
The Netherlands </p>
<p>Manufacturer 
Aesica Pharmaceuticals GmbH 
Alfred-Nobel Strasse 40789 Monheim 
Germany  </p>
<p>This leaflet was last revised in . </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-a8827a69a4f2a8d5bccee719c4738936
InstanceOf: CompositionUvEpi
Title: "Composition for cufence Package Leaflet"
Description:  "Composition for cufence Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpc0028cb0d3397ea4065a3d3cc7305a60)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - cufence"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal du vide, før du begynder at tage Cufence </li>
<li>Sådan skal du tage Cufence </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What cufence is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What cufence is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Cufence er et lægemiddel til behandling af Wilsons sygdom hos voksne, unge og børn i alderen 5 år 
og derover. Det bruges af patienter, som ikke kan tage anden medicin (D-penicillamin) på grund af 
bivirkninger. </p>
<p>Cufence indeholder det aktive stof trientin, der er et kobber-chelatdannende stof, der bruges til at 
fjerne overskydende kobber fra kroppen. Cufence binder sig til kobberet, der derefter udskilles fra 
kroppen.  </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take cufence"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take cufence"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Cufence 
Hvis du er allergisk over for trientin eller et af de øvrige indholdsstoffer (angivet i afsnit 6).  </p>
<p>Tegn på en allergisk reaktion omfatter hududslæt, kløe, hævelse i ansigtet, besvimelse og 
vejrtrækningsproblemer. </p>
<p>Advarsler og forsigtighedsregler  </p>
<p>Din læge skal regelmæssigt kontrollere dig for symptomer på sygdommen og kobberniveauerne i dit 
blod og din urin. Regelmæssig overvågning er især vigtig i starten af behandlingen, eller når din dosis 
ændres, hos børn i vækst og gravide kvinder for at sikre, at kobberniveauerne holdes på et passende 
niveau. Lægen skal eventuelt justere din dosis af Cufence op eller ned.  </p>
<p>Der kan forekomme problemer med nervesystemet (f.eks. rysten, manglende koordination, sløret tale, 
muskelstivhed og forværring af muskelspasmer), særligt hos patienter, som starter behandling med 
Cufence. Hvis du bemærker dette, mens du tager Cufence, skal du straks fortælle det til din læge. </p>
<p>Lupuslignende reaktioner (symptomer kan omfatte vedvarende hududslæt, feber, ledsmerter og 
træthed) er rapporteret hos nogle patienter, som er gået over til et lægemiddel, der indeholder trientin 
efter brug af et lægemiddel, der indeholder penicillamin. Det har dog ikke været muligt at afgøre, om 
reaktionen skyldtes trientin eller tidligere behandling med penicillamin. </p>
<p>Brug af andre lægemidler sammen med Cufence </p>
<p>Fortæl det altid til lægen eller apotekspersonalet, hvis du tager eller planlægger at tage andre 
lægemidler, eller har gjort det for nylig. </p>
<p>Hvis du tager jerntabletter eller mavesyreneutraliserende lægemidler, skal der gå mindst 2 timer, før 
eller efter du har taget Cufence, fordi de kan nedsætte virkningen af Cufence. Det anbefales at trientin 
tages mindst en time før eller efter eventuelle andre lægemidler. </p>
<p>Brug af Cufence sammen med mad og drikke </p>
<p>Tag kun dette lægemiddel sammen med vand. Tag det ikke sammen med andet, hverken drikkevarer, 
mælk eller mad, eftersom dette kan nedsætte lægemidlets virkning. Undgå at spise eller drikke 
(undtagen vand) i 2 timer før og 1 time, efter du tager Cufence. </p>
<p>Graviditet og amning </p>
<p>Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge eller apotekspersonalet til råds, før du tager dette lægemiddel. Det er meget vigtigt 
at fortsætte behandlingen for at opretholde normale kobberniveauer under graviditeten. Du og din læge 
skal tale om alle de mulige fordele ved behandlingen og tage højde for eventuelle mulige risici. Lægen 
vil rådgive dig om, hvilken behandling og hvilken dosis der er bedst i din situation. Tal med lægen, 
hvis du bliver gravid, mens du tager Cufence. </p>
<p>Hvis du er gravid og tager Cufence, vil du blive overvåget gennem hele graviditeten med hensyn til 
eventuel påvirkning af barnet eller ændringer i dine kobberniveauer.  </p>
<p>De begrænsede tilgængelige oplysninger tyder på, at Cufence ikke udskilles i modermælk, men det er 
ikke sikkert, at der ikke er nogen risiko for barnet. Det er vigtigt at fortælle lægen, om du ammer eller 
har til hensigt at gøre det. Lægen vil så hjælpe dig med at afgøre, om du skal holde op med at amme 
eller holde op med at tage Cufence, ud fra fordelen ved amning for barnet og fordelen ved Cufence for 
dig. Lægen vil afgøre, hvilken behandling og hvilken dosis der er bedst i din situation. </p>
<p>Trafik- og arbejdssikkerhed </p>
<p>Trientin vil sandsynligvis ikke påvirke din evne til at føre motorkøretøj eller betjene maskiner. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take cufence"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take cufence"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller apotekspersonalet. </p>
<p>Voksne (herunder ældre patienter) </p>
<p>Den anbefalede dosis er mellem 800 og 1 600 mg dagligt, og skal tages gennem munden. </p>
<p>Brug til børn og unge (5-17 år) </p>
<p>Hos børn og unge afhænger dosis af alder og legemsvægt, og den justeres af lægen. I starten af 
behandlingen varierer dosis mellem 400 og 1 000 mg dagligt. </p>
<p>Administration </p>
<p>Din læge fastsætter den rette dosis til dig. 
Den samlede daglige dosis kan deles i 2 til 4 mindre doser efter lægens anvisning. Kapslerne skal 
synkes hele med et glas vand på tom mave mindst 1 time før eller 2 timer efter et måltid.  </p>
<p>Patienter, som har svært ved at synke, skal kontakte deres læge. </p>
<p>Hvis du har taget for meget Cufence </p>
<p>Hvis du tager mere lægemiddel, end du skal, kan du få kvalme, kaste op eller blive svimmel. Du skal 
straks kontakte lægen eller andet sundhedspersonale. </p>
<p>Hvis du har glemt at tage Cufence </p>
<p>Hvis du har glemt at tage en dosis, skal du tage din næste dosis til den planlagte tid. 
Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis. </p>
<p>Hvis du holder op med at tage Cufence </p>
<p>Dette lægemiddel er til langtidsbehandling, fordi Wilsons sygdom er en livsvarig sygdom. Stop ikke 
behandlingen uden at tale med lægen om det, heller ikke selvom du får det bedre. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. 
Undertiden (hyppighed ukendt; kan ikke estimeres ud fra de foreliggende data) kan behandling med 
dette lægemiddel forårsage inflammation i tyndtarmen eller endetarmen. Hvis du får nogen af følgende 
bivirkninger, skal du øjeblikkeligt kontakte lægen:</p>
<ul>
<li>Stærke mavesmerter </li>
<li>Vedvarende diarré </li>
<li>Problemer med nervesystemet (f.eks. rysten, manglende koordination, sløret tale, muskelstivhed, 
forværring af muskelspasmer).  </li>
</ul>
<p>Andre bivirkninger kan omfatte: 
Almindelige (kan forekomme hos op til 1 ud af 10 personer) 
- Kvalme (især i starten af behandlingen) </p>
<p>Ikke almindelige (kan forekomme hos op til 1 ud af 100 personer) 
- Hududslæt 
- Anæmi (du kan føle dig usædvanlig træt) </p>
<p>Indberetning af bivirkninger </p>
<p>Hvis du oplever bivirkninger, bør du tale med din læge, apotekspersonalet eller sygeplejersken. Dette 
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende 
kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store cufence"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store cufence"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Tag ikke lægemidlet efter den udløbsdato, der står på etiketten og æsken efter EXP. Udløbsdatoen er 
den sidste dag i den nævnte måned.  </p>
<p>Anvendes senest 3 måneder efter anbrud. Hold flasken tæt tillukket for at beskytte mod fugt. Tag ikke 
kapslerne, hvis de er klæbrige eller våde. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe lægemiddelrester. Af hensyn til miljøet må du 
ikke smide lægemiddelrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Cufence indeholder: </p>
<p>Aktivt stof: trientin.<br />
- Hver hårde kapsel Cufence 100 mg indeholder 150 mg trientindihydrochlorid svarende til 100 mg 
trientin. 
- Hver hårde kapsel Cufence 200 mg indeholder 300 mg trientindihydrochlorid svarende til 200 mg 
trientin. </p>
<p>Øvrige indholdsstoffer:</p>
<ul>
<li>Kapslens indhold: Magnesiumstearat, colloid vandfri silica </li>
<li>Kapslens skal: Gelatine, titandioxid (E171) </li>
<li>Trykfarve: Shellac, propylenglykol (E1520), titandioxid (E171), sort jernoxid (E 172), gul 
jernoxid (E172) </li>
</ul>
<p>Udseende og pakningsstørrelser </p>
<p>Cufence 100 mg hårde kapsler 
Hvid, uigennemsigtig HDPE-flaske med børnesikret HDPE-skruelåg og varmeinduceret 
forseglingsindsats med en pose tørret silicagel som tørremiddel. Hver hård kapsel er hvid, oval, 
størrelse 3 (15,8 mm x 5,85 mm) med ’Cufence 100’ trykt med gråt blæk. </p>
<p>Pakningsstørrelser: En beholder med 200 hårde kapsler.  </p>
<p>Cufence 200 mg hårde kapsler 
Gul glasflaske med polypropylenhætte og varmeinduceret forseglingsindsats med en pose tørret 
silicagel som tørremiddel. Hver hård kapsel er hvid, oval, størrelse 0 (21,8 mm x 7,66 mm) med 
’Cufence’ trykt med gråt blæk. </p>
<p>Pakningsstørrelser: En beholder med 100 hårde kapsler.  </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen 
Univar Solutions BV 
Schouwburgplein 3012 CL Rotterdam 
Holland </p>
<p>Fremstiller 
Aesica Pharmaceuticals GmbH 
Alfred-Nobel Strasse 40789 Monheim 
Tyskland  </p>
<p>Denne indlægsseddel blev senest ændret. </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside https://www.ema.europa.eu<br />
Der er også links til andre websteder om sjældne sygdomme og om, hvordan de behandles. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-a8827a69a4f2a8d5bccee719c4738936
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for cufence Package Leaflet for language en"
Description: "ePI document Bundle for cufence Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-a8827a69a4f2a8d5bccee719c4738936"
* entry[0].resource = composition-en-a8827a69a4f2a8d5bccee719c4738936

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpa8827a69a4f2a8d5bccee719c4738936"
* entry[=].resource = mpa8827a69a4f2a8d5bccee719c4738936
                            
                    
Instance: bundlepackageleaflet-da-a8827a69a4f2a8d5bccee719c4738936
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for cufence Package Leaflet for language da"
Description: "ePI document Bundle for cufence Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-a8827a69a4f2a8d5bccee719c4738936"
* entry[0].resource = composition-da-a8827a69a4f2a8d5bccee719c4738936

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpa8827a69a4f2a8d5bccee719c4738936"
* entry[=].resource = mpa8827a69a4f2a8d5bccee719c4738936
                            
                    



Instance: mpa8827a69a4f2a8d5bccee719c4738936
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Cufence 100 mg hard capsules"
Description: "Cufence 100 mg hard capsules"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/19/1365/002"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Cufence 100 mg hard capsules"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: a8827a69a4f2a8d5bccee719c4738936ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "cufence"

* status = #current
* mode = #working

* title = "List of all ePIs associated with cufence"

* subject = Reference(mpc0028cb0d3397ea4065a3d3cc7305a60)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#cufence "cufence"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-a8827a69a4f2a8d5bccee719c4738936) // cufence en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-a8827a69a4f2a8d5bccee719c4738936) // cufence da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-a8827a69a4f2a8d5bccee719c4738936
InstanceOf: List

* insert a8827a69a4f2a8d5bccee719c4738936ListRuleset
    